Checkpoint Therapeutics Valuation
| CKPT Stock | USD 3.47 0.09 2.66% |
At this time, the firm appears to be undervalued. Checkpoint Therapeutics shows a prevailing Real Value of $8.27 per share. The current price of the firm is $3.47. Our model approximates the value of Checkpoint Therapeutics from analyzing the firm fundamentals such as return on equity of -12.2, and Operating Margin of (162.76) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Checkpoint Therapeutics' valuation include:
Price Book 8.5555 | Enterprise Value 160.4 M | Enterprise Value Ebitda (0.54) | Price Sales 2.1 K | Enterprise Value Revenue 3.4 K |
Undervalued
Today
Please note that Checkpoint Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Checkpoint Therapeutics is based on 3 months time horizon. Increasing Checkpoint Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Checkpoint Therapeutics' intrinsic value may or may not be the same as its current market price of 3.47, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.47 | Real 8.27 | Target 23.4 | Hype 3.56 | Naive 3.34 |
The intrinsic value of Checkpoint Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Checkpoint Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Checkpoint Therapeutics helps investors to forecast how Checkpoint stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Checkpoint Therapeutics more accurately as focusing exclusively on Checkpoint Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Checkpoint Therapeutics' intrinsic value based on its ongoing forecasts of Checkpoint Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Checkpoint Therapeutics' closest peers.
Checkpoint Therapeutics Cash |
|
Checkpoint Valuation Trend
Checkpoint Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Checkpoint Therapeutics' financial worth over time. Using both Checkpoint Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Checkpoint Therapeutics Total Value Analysis
Checkpoint Therapeutics is currently projected to have valuation of 160.35 M with market capitalization of 165.05 M, debt of 18.43 M, and cash on hands of 30.89 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Checkpoint Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
160.35 M | 165.05 M | 18.43 M | 30.89 M |
Checkpoint Therapeutics Investor Information
About 16.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.83. Checkpoint Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 6th of December 2022. Based on the key indicators related to Checkpoint Therapeutics' liquidity, profitability, solvency, and operating efficiency, Checkpoint Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Checkpoint Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Checkpoint Therapeutics has an asset utilization ratio of 1.92 percent. This implies that the Company is making $0.0192 for each dollar of assets. An increasing asset utilization means that Checkpoint Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Checkpoint Therapeutics Ownership Allocation
Checkpoint Therapeutics holds a total of 48.13 Million outstanding shares. Checkpoint Therapeutics shows 15.51 percent of its outstanding shares held by insiders and 13.91 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Checkpoint Therapeutics Profitability Analysis
The company reported the previous year's revenue of 103 K. Net Loss for the year was (51.85 M) with loss before overhead, payroll, taxes, and interest of (48.19 M).About Checkpoint Therapeutics Valuation
The stock valuation mechanism determines Checkpoint Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Checkpoint Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Checkpoint Therapeutics. We calculate exposure to Checkpoint Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Checkpoint Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -43.5 M | -41.3 M | |
| Pretax Profit Margin | (503.37) | (478.20) | |
| Operating Profit Margin | (506.29) | (480.98) | |
| Net Loss | (503.37) | (478.20) | |
| Gross Profit Margin | (421.97) | (400.87) |
Checkpoint Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Checkpoint Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 18.7 M |
Checkpoint Therapeutics Current Valuation Indicators
Checkpoint Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Checkpoint Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Checkpoint Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Checkpoint Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Checkpoint Therapeutics' worth.Additional Tools for Checkpoint Stock Analysis
When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.